Research Summary

My research efforts are focused on the development and testing of novel, biologically based therapies for low- and high-grade neuroendocrine neoplasms (NENs). Additional research areas include clinical outcomes, molecular subtyping, and novel imaging endpoints in NENs. I am past-chair of the GI Oncology site committee and an active member of the Phase I site committee at UCSF. Nationally, I am past-chair of the Neuroendocrine Tumor Task Force of the National Cancer Institute (NCI) Gastrointestinal Steering Committee, past president of the North American Neuroendocrine Tumor Society (NANETS), and current chair of the NCCN Neuroendocrine Tumors Guidelines Panel.

Research Funding

  • July 1, 2021 - June 30, 2026 - UCSF Paul Calabresi K12 Career Development Program in Clinical Oncology , Principal Investigator . Sponsor: NIH, Sponsor Award ID: K12CA260225


University of Wisconsin, B.S., 1985, Biochemistry and Molecular Biology
University of Minnesota, M.D., 1982

Honors & Awards

  • 2009
    Fellow, American College of Physicians
  • 2009
    Helen Diller Family Quality Award
  • 2013, 2015, 2016, 2018, 2019, 2020
    Castle Connolly's Top Doctors™, Castle Connolly/San Francisco Magazine
  • 2014
    Graduate, UCSF Mentor Development Program
  • 2017-2020
    Exceptional Women in Medicine, Castle Connolly
  • 2017
    Ernest H. Rosenbaum, MD Commitment to Patient Care Award, UCSF, Symptom Management Service
  • 2019
    Great Experience Award (for Neuroendocrine Tumor Patient/Caregiver All-day Conference), UCSF
  • 2023
    Fellow, American Society of Clinical Oncology

Selected Publications

  1. Del Rivero J, Perez K, Kennedy EB, Mittra ES, Vijayvergia N, Arshad J, Basu S, Chauhan A, Dasari AN, Bellizzi AM, Gangi A, Grady E, Howe JR, Ivanidze J, Lewis M, Mailman J, Raj N, Soares HP, Soulen MC, White SB, Chan JA, Kunz PL, Singh S, Halfdanarson TR, Strosberg JR, Bergsland EK. Systemic Therapy for Tumor Control in Metastatic Well-Differentiated Gastroenteropancreatic Neuroendocrine Tumors: ASCO Guideline. J Clin Oncol. 2023 Sep 29; JCO2301529.  View on PubMed
  2. Majmudar S, Graff SL, Kays M, Braz BX, Matt-Amaral L, Markham MJ, Subbiah IM, Bergsland E, Jain S. The Careers and Professional Well-Being of Women Oncologists During the COVID-19 Pandemic: Responding for Tomorrow. J Med Internet Res. 2023 08 21; 25:e47784.  View on PubMed
  3. Varghese DG, Del Rivero J, Bergsland E. Grade Progression and Intrapatient Tumor Heterogeneity as Potential Contributors to Resistance in Gastroenteropancreatic Neuroendocrine Tumors. Cancers (Basel). 2023 Jul 21; 15(14).  View on PubMed
  4. Keenan BP, Sibley A, Zhang L, Westring AF, Velazquez AI, Bank EM, Bergsland EK, Boreta L, Conroy P, Daras M, Hermiston M, Hsu G, Paris PL, Piawah S, Sinha S, Sosa JA, Tsang M, Venook AP, Wong M, Yom SS, Van Loon K. Evaluation of Culture Conducive to Academic Success by Gender at a Comprehensive Cancer Center. Oncologist. 2023 Jul 13.  View on PubMed
  5. Eads JR, Halfdanarson TR, Asmis T, Bellizzi AM, Bergsland EK, Dasari A, El-Haddad G, Frumovitz M, Meyer J, Mittra E, Myrehaug S, Nakakura E, Raj N, Soares HP, Untch B, Vijayvergia N, Chan JA. Expert Consensus Practice Recommendations of the North American Neuroendocrine Tumor Society for the management of high grade gastroenteropancreatic and gynecologic neuroendocrine neoplasms. Endocr Relat Cancer. 2023 08 01; 30(8).  View on PubMed
  6. Sedlack AJH, Hatfield SJ, Kumar S, Arakawa Y, Roper N, Sun NY, Nilubol N, Kiseljak-Vassiliades K, Hoang CD, Bergsland EK, Hernandez JM, Pommier Y, Del Rivero J. Preclinical Models of Adrenocortical Cancer. Cancers (Basel). 2023 May 23; 15(11).  View on PubMed
  7. Raj N, Chan JA, Wang SJ, Aggarwal RR, Calabrese S, DeMore A, Fong L, Grabowsky J, Hope TA, Kolli KP, Mulvey CK, Munster PN, Perez K, Punn S, Reidy-Lagunes D, Von Fedak S, Zhang L, Bergsland EK. Pembrolizumab alone and pembrolizumab plus chemotherapy in previously treated, extrapulmonary poorly differentiated neuroendocrine carcinomas. Br J Cancer. 2023 08; 129(2):291-300.  View on PubMed
  8. Wang SJ, Whitman J, Paciorek A, Le BK, Nakakura EK, Behr SC, Joseph N, Zhang L, Hope TA, Bergsland EK. Baseline tumor growth rate highlights the heterogeneity of well differentiated gastroenteropancreatic neuroendocrine tumors and predicts for increases in Ki67 index over time. J Neuroendocrinol. 2023 04; 35(4):e13260.  View on PubMed
  9. Le BK, McGarrah P, Paciorek A, Mohamed A, Apolo AB, Chan DL, Reidy-Lagunes D, Hauser H, Rivero JD, Whitman J, Batty K, Zhang L, Raj N, Le T, Bergsland E, Halfdanarson TR. Urinary Neuroendocrine Neoplasms Treated in the "Modern Era": A Multicenter Retrospective Review. Clin Genitourin Cancer. 2023 06; 21(3):403-414.e5.  View on PubMed
  10. Das S, Phillips S, Lee CL, Agarwal R, Bergsland E, Strosberg J, Chan JA, LaFerriere H, Ramirez RA, Berlin J, Dasari A. Efficacy and toxicity of anti-vascular endothelial growth receptor tyrosine kinase inhibitors in patients with neuroendocrine tumours - A systematic review and meta-analysis. Eur J Cancer. 2023 Mar; 182:43-52.  View on PubMed
  11. Umetsu SE, Kakar S, Basturk O, Kim GE, Chatterjee D, Wen KW, Hale G, Shafizadeh N, Cho SJ, Whitman J, Gill RM, Jones KD, Navale P, Bergsland E, Klimstra D, Joseph NM. Integrated Genomic and Clinicopathologic Approach Distinguishes Pancreatic Grade 3 Neuroendocrine Tumor From Neuroendocrine Carcinoma and Identifies a Subset With Molecular Overlap. Mod Pathol. 2023 03; 36(3):100065.  View on PubMed
  12. Sedlack AJH, Saleh-Anaraki K, Kumar S, Ear PH, Lines KE, Roper N, Pacak K, Bergsland E, Quelle DE, Howe JR, Pommier Y, Del Rivero J. Preclinical Models of Neuroendocrine Neoplasia. Cancers (Basel). 2022 Nov 17; 14(22).  View on PubMed
  13. Yao J, Bergsland E, Aggarwal R, Aparicio A, Beltran H, Crabtree JS, Hann CL, Ibrahim T, Byers LA, Sasano H, Umejiego J, Pavel M. DLL3 as an Emerging Target for the Treatment of Neuroendocrine Neoplasms. Oncologist. 2022 11 03; 27(11):940-951.  View on PubMed
  14. Tsang ES, Aggarwal RR, Dhawan MS, Bergsland EK, Alvarez EA, Calabrese S, Pacaud R, Garcia J, Fattah D, Thomas S, Grabowsky J, Moasser MM, Munster PN. A Phase IB Trial of the PI3K Inhibitor Alpelisib and Weekly Cisplatin in Patients with Solid Tumor Malignancies. Cancer Res Commun. 2022 07; 2(7):570-576.  View on PubMed
  15. Sun F, Grenert JP, Tan L, Van Ziffle J, Joseph NM, Mulvey CK, Bergsland E. Checkpoint Inhibitor Immunotherapy to Treat Temozolomide-Associated Hypermutation in Advanced Atypical Carcinoid Tumor of the Lung. JCO Precis Oncol. 2022 06; 6:e2200009.  View on PubMed
  16. Hope TA, Pavel M, Bergsland EK. Neuroendocrine Tumors and Peptide Receptor Radionuclide Therapy: When Is the Right Time? J Clin Oncol. 2022 08 20; 40(24):2818-2829.  View on PubMed
  17. Galgano SJ, Morani AC, Gopireddy DR, Sharbidre K, Bates DDB, Goenka AH, Arif-Tiwari H, Itani M, Iravani A, Javadi S, Faria S, Lall C, Bergsland E, Verma S, Francis IR, Halperin DM, Chatterjee D, Bhosale P, Yano M. Pancreatic neuroendocrine neoplasms: a 2022 update for radiologists. Abdom Radiol (NY). 2022 Dec; 47(12):3962-3970.  View on PubMed
  18. Baxter NN, Kennedy EB, Bergsland E, Berlin J, George TJ, Gill S, Gold PJ, Hantel A, Jones L, Lieu C, Mahmoud N, Morris AM, Ruiz-Garcia E, You YN, Meyerhardt JA. Adjuvant Therapy for Stage II Colon Cancer: ASCO Guideline Update. J Clin Oncol. 2022 03 10; 40(8):892-910.  View on PubMed
  19. Sun N, Yang Y, Miao H, Redublo P, Liu H, Liu W, Huang YW, Teng PC, Zhang C, Zhang RY, Smalley M, Yang P, Chou SJ, Huai K, Zhang Z, Lee YT, Wang JJ, Wang J, Liang IY, Zhang TX, Zhang D, Liang L, Weiss PS, Posadas EM, Donahue T, Hecht JR, Allen-Auerbach MS, Bergsland EK, Hope TA, Pei R, Zhu Y, Tseng HR, Heaney AP. Discovery and characterization of circulating tumor cell clusters in neuroendocrine tumor patients using nanosubstrate-embedded microchips. Biosens Bioelectron. 2022 Mar 01; 199:113854.  View on PubMed
  20. Kasai Y, Masui T, Nakakura EK, Nakano K, Sato A, Uchida Y, Yogo A, Nagai K, Anazawa T, Hope TA, Kim GE, Whitman J, Le BK, Takaori K, Bergsland EK, Hatano E, Uemoto S. Preoperative risk stratification of lymph node metastasis for non-functional pancreatic neuroendocrine neoplasm: An international dual-institutional study. Pancreatology. 2022 Jan; 22(1):123-129.  View on PubMed

Go to UCSF Profiles, powered by CTSI